Literature DB >> 19856150

[Medical insurance aspects of peritoneal tumors with particular attention to peritoneal mesotheliomas].

Volker Neumann1, Stefan Löseke, Andrea Tannapfel.   

Abstract

Malignant peritoneal mesotheliomas arise mainly in male patients and the median age of initial diagnosis is about 56 years. Epitheloid subtype predominates in peritoneal mesotheliomas. Asbestos exposure is the best-known and most common risk factor associated with the development of both pleural and peritoneal mesotheliomas and, therefore, about 90% of cases can be assessed as asbestos-associated. Patients with peritoneal mesotheliomas have distinctly higher asbestos burden of the lungs than patients with pleural mesotheliomas. The mean latency period between exposure and diagnosis of peritoneal mesothelioma ranges from 35 to 40 years and is comparable to that of pleural mesothelioma. Mesothelioma of the tunica vaginalis testis also belongs to the group of peritoneal mesotheliomas. No significant evidence exists for the classification of well-differentiated papillary mesothelioma, solitary fibrous tumor, adenomatoid tumor, primary peritoneal serous borderline tumor, and benign multicystic mesothelioma as asbestos-associated tumors. Except malignant mesotheliomas, the induction of other abdominal tumors is independent of an exposure to asbestos dust.

Entities:  

Mesh:

Year:  2009        PMID: 19856150     DOI: 10.1007/s00063-009-1162-z

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  66 in total

1.  Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province.

Authors:  J C WAGNER; C A SLEGGS; P MARCHAND
Journal:  Br J Ind Med       Date:  1960-10

Review 2.  Nonpleural mesotheliomas: mesothelioma of the peritoneum, tunica vaginalis, and pericardium.

Authors:  Raffit Hassan; Richard Alexander
Journal:  Hematol Oncol Clin North Am       Date:  2005-12       Impact factor: 3.722

3.  Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma.

Authors:  Mary E Hesdorffer; John A Chabot; Mary Louise Keohan; Karen Fountain; Susan Talbot; Michelle Gabay; Catherine Valentin; Shing M Lee; Robert N Taub
Journal:  Am J Clin Oncol       Date:  2008-02       Impact factor: 2.339

4.  The clinical aspects of mesothelioma.

Authors:  P C Elmes; J C Simpson
Journal:  Q J Med       Date:  1976-07

5.  Migration of ingested asbestos.

Authors:  J H Kaczenski; W H Hallenbeck
Journal:  Environ Res       Date:  1984-12       Impact factor: 6.498

6.  Malignant deciduoid mesothelioma: a diagnostic challenge.

Authors:  Najat Mourra; Cecile de Chaisemartin; Isabelle Goubin-Versini; Rolland Parc; Jean-Francois Flejou
Journal:  Arch Pathol Lab Med       Date:  2005-03       Impact factor: 5.534

Review 7.  Epidemiology of peritoneal mesothelioma: a review.

Authors:  P Boffetta
Journal:  Ann Oncol       Date:  2006-10-09       Impact factor: 32.976

8.  Asbestos-related mesothelioma: factors discriminating between pleural and peritoneal sites.

Authors:  K Browne; W J Smither
Journal:  Br J Ind Med       Date:  1983-05

9.  Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors.

Authors:  J Goldblum; W R Hart
Journal:  Am J Surg Pathol       Date:  1995-10       Impact factor: 6.394

10.  Serous borderline tumors of the peritoneum.

Authors:  D A Bell; R E Scully
Journal:  Am J Surg Pathol       Date:  1990-03       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.